|1.||Koch, Tad H: 7 articles (07/2012 - 12/2005)|
|2.||Barthel, Benjamin L: 6 articles (07/2012 - 12/2005)|
|3.||Burkhart, David J: 4 articles (07/2012 - 12/2005)|
|4.||Rudnicki, Daniel L: 3 articles (07/2012 - 01/2008)|
|5.||Post, Glen C: 3 articles (01/2008 - 12/2005)|
|6.||Kalet, Brian T: 3 articles (01/2008 - 11/2006)|
|7.||Guo, Liangran: 1 article (04/2013)|
|8.||Xiao, Da: 1 article (04/2013)|
|9.||Yang, Dongfang: 1 article (04/2013)|
|10.||Yan, Bingfang: 1 article (04/2013)|
07/26/2012 - "We demonstrate that activation of GaFK-Doxaz releases highly potent doxaz that powerfully inhibits the growth of a wide variety of cancer cells (average IC(50) of 8 nM). "
07/26/2012 - "Here, we describe the synthesis and characterization of a prodrug platform designed for doxaz release mediated by secreted proteolytic activity, a common association with invasiveness and poor prognosis in cancer patients. "
09/06/2007 - "The IC(50) for growth inhibition of 67 human cancer cell lines, but not cardiomyocytes, is 32-fold lower with doxazolidine than with doxorubicin. "
11/30/2006 - "The synthesis and tumor cell growth inhibition by doxazolidine carbamate prodrugs are reported. "
12/10/2009 - "Finally, we demonstrate that cellular response to PPD may be predicted with good accuracy using CES2 expression and Doxaz sensitivity, suggesting that these metrics may be useful as clinical biomarkers for sensitivity of a specific tumor to PPD treatment."
|2.||Thyroid Neoplasms (Thyroid Cancer)
|5.||Carboxylesterase (Hydrolase S)
|6.||Biological Markers (Surrogate Marker)
|9.||Proteins (Proteins, Gene)